体外转录模板市场 - 按产品类型、疾病、治疗、研究阶段、最终用途 - 全球预测

在分子生物学的进步以及对基于 RNA 的治疗和诊断的需求不断增长的推动下，体外转录模板市场规模预计在 2024 年至 2032 年间将以 19.6% 的复合年增长率增长。体外转录模板在产生用于研究和工业应用的 RNA 分子方面发挥着至关重要的作用，包括 RNA 疫苗开发、基因表现研究和 RNA 定序。 RNA技术研究的兴起，特别是用于传染病和癌症免疫疗法的mRNA疫苗，也增加了对高品质体外转录模板的需求。

更有效率、更具成本效益的转录系统的开发以及改进的模板设计技术提高了 RNA 生产的可扩展性和可重复性。基于 RNA 的诊断技术的日益普及，特别是在传染病爆发期间和遗传性疾病期间，将进一步刺激产品需求。

该行业分为产品类型、疾病、治疗、研究阶段、最终用途和地区。

根据产品类型，RNA 模板细分市场预计将在2024 年至2032 年间在体外转录模板市场中成长。疫苗、RNA 干扰疗法和RNA诊断。一些科学和医学界也持续探索和扩大 RNA 技术的应用，进一步推动该领域的成长。

按疾病划分，生活方式疾病细分市场的体外转录模板行业预计将在2024 年至2032 年实现显着的复合年增长率。 ，例如糖尿病、心血管疾病、和肥胖。这些疾病通常涉及复杂的分子机制，进一步需要基因表现分析和 RNA 分析。

亚太地区体外转录模板市场预计从 2024 年到 2032 年将出现显着增长。此外，中国、印度和日本等国家日益关注个人化医疗以及慢性病盛行率的上升，推动了对高效 RNA 生产方法的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 基因组学和转录组学的进展
    • 对 mRNA 疫苗和治疗药物的需求不断增加
    • 分子生物学研究与发展
  • 产业陷阱与挑战
    • 可及性和承受能力有限
    • 严格的监管挑战
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

• 主要趋势
• DNA模板
• RNA模板
• 模板和转录套件
• 其他产品类型

第 6 章：市场估计与预测：按疾病分类，2021 - 2032 年

• 主要趋势
• 癌症
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 摄护腺癌
  • 白血病
  • 卵巢癌
  • 其他癌症
• 传染病
  • 流感
  • 伊波拉病毒
  • 丙型肝炎病毒
  • 人类免疫缺乏病毒（HIV）
  • 登革热病毒
  • 其他传染病
• 生活方式疾病
• 遗传疾病
• 其他疾病

第 7 章：市场估计与预测：按处理方式，2021 - 2032

• 主要趋势
• 疫苗
• 治疗性

第 8 章：市场估计与预测：按研究阶段划分，2021 年 - 2032 年

• 主要趋势
• 探索性
• 临床

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 生物技术和製药公司
• 学术及研究机构
• 合约研究组织

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Agilent Technologies Inc.
• Bio-Synthesis Inc.
• Bio-Rad Laboratories Inc.
• CINVEN LIMITED
• Danaher Corporation
• Enzynomics Co Ltd.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina Inc.
• LGC Limited
• Merck KGaA
• Promega Corporation
• Qiagen N.V.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

In-vitro transcription templates market size is anticipated to grow at 19.6% CAGR between 2024 and 2032, driven by advancements in molecular biology and the increasing demand for RNA-based therapeutics and diagnostics. In-vitro transcription templates play a crucial role in generating RNA molecules for research and industrial applications, including RNA vaccine development, gene expression studies, and RNA sequencing. The rise in RNA technology research, especially mRNA vaccines for infectious diseases and cancer immunotherapies, has also heightened the demand for high-quality in-vitro transcription templates.

The development of more efficient and cost-effective transcription systems, along with improved template design techniques has boosted the scalability and reproducibility of RNA production. The rising adoption of RNA-based diagnostics, especially during infectious disease outbreaks and for genetic disorders will further fuel the product demand.

The industry is segmented into product type, disease, treatment, research stage, end-use, and region.

Based on product type, the RNA templates segment is poised to grow in the in-vitro transcription templates market between 2024 and 2032. This dominance is due to its pivotal role in producing high-quality RNA for various applications, including mRNA vaccines, RNA interference therapies, and RNA diagnostics. Several scientific and medical communities are also continuing to explore and expand the applications of RNA technology, further driving the segment growth.

By disease, the in-vitro transcription templates industry from the lifestyle diseases segment is set to witness significant CAGR from 2024 to 2032. This is driven by the growing emphasis on understanding and treating diseases associated with lifestyle factors, such as diabetes, cardiovascular diseases, and obesity. These diseases often involve intricate molecular mechanisms, further necessitating gene expression analysis and RNA profiling.

Asia Pacific in-vitro transcription templates market is expected to witness notable growth from 2024 to 2032. This growth can be attributed to rapid biotechnological advancements, increased research investments, and the rising demand for RNA-based therapies and diagnostics. Moreover, countries like China, India, and Japan, with their increasing focus on personalized medicine and the rising prevalence of chronic diseases, are propelling the need for efficient RNA production methods.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in genomics and transcriptomics
    • 3.2.1.2 Increasing demand for mRNA vaccines and therapeutics
    • 3.2.1.3 Research and development in molecular biology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited accessibility and affordability
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 DNA templates
• 5.3 RNA templates
• 5.4 Templates and transcription kits
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
  • 6.2.1 Lung cancer
  • 6.2.2 Breast cancer
  • 6.2.3 Colorectal cancer
  • 6.2.4 Prostate cancer
  • 6.2.5 Leukemia
  • 6.2.6 Ovarian cancer
  • 6.2.7 Other cancers
• 6.3 Infectious disease
  • 6.3.1 Influenza
  • 6.3.2 Ebola virus
  • 6.3.3 Hepatitis C virus
  • 6.3.4 Human immunodeficiency virus (HIV)
  • 6.3.5 Dengue virus
  • 6.3.6 Other infectious diseases
• 6.4 Lifestyle disease
• 6.5 Genetic disease
• 6.6 Other diseases

Chapter 7 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Vaccine
• 7.3 Therapeutic

Chapter 8 Market Estimates and Forecast, By Research Stage, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Exploratory
• 8.3 Clinical

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Biotechnology and pharmaceutical companies
• 9.3 Academic and research institutes
• 9.4 Contract research organizations

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Agilent Technologies Inc.
• 11.2 Bio-Synthesis Inc.
• 11.3 Bio-Rad Laboratories Inc.
• 11.4 CINVEN LIMITED
• 11.5 Danaher Corporation
• 11.6 Enzynomics Co Ltd.
• 11.7 Enzo Biochem Inc.
• 11.8 F. Hoffmann-La Roche Ltd.
• 11.9 Illumina Inc.
• 11.10 LGC Limited
• 11.11 Merck KGaA
• 11.12 Promega Corporation
• 11.13 Qiagen N.V.
• 11.14 Takara Bio Inc.
• 11.15 Thermo Fisher Scientific Inc.